logo
    • English
      • 简体中文
      • 繁體中文
  • Home
  • Articles
    • Insights
    • Client Press Releases
    • Client Coverage
  • Interviews
    • CEO Interview
    • PDAC Interview
  • Clients
    • Featured Companies
    • In-depth Analysis
  • Markets
    • Stock Tracker
    • Markets at a glance
    • Investing 101
      • Investing in Mining 101
        • Gold and Precious Metals
        • Electric and Battery Metals
        • Base Metals
        • Other Mining Subsectors
  • METALS 100
  • GCFF Event
    • Next Event
    • Past Events
  • Home
  • Genomics
Filter

Genomics

Categories

Sectors

Locations

Exchange

Gilead Starts China Phase III Trial of Remdesivir in Coronavirus Patients

Feb 4, 2020

Life Science

医疗保健精选——百时美施贵宝和BioMotiv成立新药合资企业,百特获得内毒素过滤器的许可授权

Healthcare Roundup – Bristol-Myers and BioMotiv launch new drug venture, Baxter in-licenses rights to endotoxin filter

Feb 4, 2020

Life Science

AntiCancer Inc.口服重组蛋氨酸酶有望杀死2019-nCoV冠状病毒

AntiCancer Inc. to Target Its Oral Recombinant Methioninase Against 2019-nCoV Coronavirus

Feb 3, 2020

Technology

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

Commercial-Grade Replicel Injectors RepliCel in Production

Feb 3, 2020

Technology

中国江苏省开发快速鉴定新型冠状病毒的检测试剂盒

Jiangsu Province Develops Test Kit for Rapid Identification of Novel Coronavirus

Jan 31, 2020

Life Science

医疗保健精选——强生疫苗对决冠状病毒,Selecta Biosciences下跌5.17%

Healthcare Roundup – J&J enters coronavirus fray with planned vaccine, Selecta Biosciences -5.7%

Jan 29, 2020

Life Science

冠状病毒恐惧情绪,香港股市应声下跌近3%

Hong Kong Stock Market Dives Nearly 3% on Coronavirus Fears

Jan 29, 2020

Life Science

控制冠状病毒爆发,中国科学家全力以赴

Chinese Scientists Provide Support to Control Coronavirus Outbreak

Jan 27, 2020

Life Science

默克的Keytruda迎挑战,百济神州Tislelizumab鳞状非小细胞肺癌

BeiGene’s Tislelizumab Could Challenge Merck’s Keytruda in the Checkpoint Inhibitor Market

Jan 24, 2020

Life Science

歌禮製藥ASC22有望成為HBV一流免疫療法

Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22, a Subcutaneously Administered PD-L1 Antibody

Jan 23, 2020

Life Science

专注女性健康的Mycovia Pharmaceuticals管理层“换血”

Mycovia Pharmaceuticals Expands Commercialization Team with Strategic New Hires

Jan 21, 2020

Life Science

美国制药公司纷纷降价,原因一探

Pharma Companies Cut Prices of Off-Patent Drugs to Compete in China’s Bulk-Buy Program

Jan 20, 2020

Life Science

丹诺医药一款新药获美国FDA孤儿药认定

TenNor Therapeutics Received FDA Orphan Drug Designation

Jan 20, 2020

Life Science

医疗保健精选——礼来Jardiance仿制药获批,Endra与GE医疗合作

Healthcare Roundup – FDA OK generic version of Lilly’s Jardiance, Endra re-ups with GE Healthcare

Jan 15, 2020

Life Science

医疗保健精选——信诺与奥斯卡健保合作,Qiagen与安进合作

Healthcare – Cigna teams up with Oscar, Qiagen teams up with Amgen

Jan 13, 2020

Life Science

中国生物制药携手美国企业,开发下一代生物制剂

Ambrx and Sino Biopharma Announce Collaboration to Develop Two Next-Generation Biologics

Jan 13, 2020

Life Science

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

RepliCel Announces its Incoming Board of Directors

Dec 23, 2019

Life Science

基石药业 CS3005

CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia

Dec 12, 2019

Life Science

  • ‹‹ Previous
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • Next ››

We connect Investors to Opportunities.

Financial Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

 
QuoteMedia logo

Head Office

  • 2209 – 1111 Alberni Street
    Vancouver, BC Canada V6E 4V2
  • Phone: (604) 488-8878
  • Fax: (604) 488-0868
  • Toll Free: 1 (866) 833-5517
  • Email: [email protected]

Shanghai Office

  • 06 - 607, 6/f. No.800 Shangcheng
    Road Pudong New District Shanghai,
    China
  • Phone: 021-68883919
  • Fax: 021-68882879
  • Email: [email protected]

Important Links

  • Privacy Policy
  • Terms of Use
  • Content Partner
  • NAI500 Investor Relations Services
  • About Us
  • Contact Us

© 2026 NAI Interactive Ltd. All Rights Reserved

gcff

logo

Website Design Vancouver by Nirvana Canada